| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab130870-10μl | 10μl | In stock | $66.90 | |
| Ab130870-50μl | 50μl | In stock | $199.90 | |
| Ab130870-100μl | 100μl | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $279.90 | |
| Ab130870-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,499.90 |
pAb; Rabbit anti Human TGF beta Receptor I Antibody; WB, ICC, IF; Unconjugated
| Product Name | TGF beta Receptor I Antibody - Primary antibody, specific to TGFBR1, Rabbit IgG |
|---|---|
| Synonyms | TGFBR1 | ALK5 | SKR4 | TGF-beta receptor type-1 | TGFR-1 | Activin A receptor type II-like protein kinase of 53kD | Activin receptor-like kinase 5 | ALK-5 | Serine/threonine-protein kinase receptor R4 | TGF-beta type I receptor | TGF beta Receptor I Rabbi |
| Specifications & Purity | ExactAb™, Validated, 1.0 mg/mL |
| Host species | Rabbit |
| Specificity | TGFBR1 |
| Immunogen | A synthetic peptide derived from human TGFBR1 (AA 157-244) |
| Positive Control | WB: C6, NIH/3T3, RAW 264.7, MOLT-4, A431, Jurkat, HeLa and HepG2 cell lysates. ICC/IF: HeLa cells. |
| Conjugation | Unconjugated |
| Grade | ExactAb™, Validated |
| Product Description | Rabbit anti Human TGF beta Receptor I Antibody, Polyclonal, could be used for WB, ICC, IF and so on. |
| Isotype | Rabbit IgG |
|---|---|
| SDS-PAGE | 150 kDa |
| Purification Method | Protein A purified |
| Form | Liquid |
| Concentration | 1.0 mg/mL |
| Storage Temp | Store at -20°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle. |
TGF beta Receptor I Antibody (Ab130870) - Western Blot
All lanes: TGF beta Receptor I Antibody (Ab130870) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution
Predicted band size: 52 kDa
Observed band size: 56 kDa
Exposure time: 0.5 s
TGF beta Receptor I Antibody (Ab130870) - IF/ICC
Immunofluorescence analysis of TGF beta Receptor I in HeLa using TGF beta Receptor I Antibody (Ab130870).
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Application | Dilution info |
|---|---|
| WB | 1/500-1/1000"> 1/500-1/1000 |
| IF/ICC | 1/100-1/200 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0102521 | Certificate of Analysis | Jan 18, 2024 | Ab130870 |
| ZJ24F0102520 | Certificate of Analysis | Jan 18, 2024 | Ab130870 |
| 1. Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T, Herron DK, Li HY, McMillen WT, Mort N et al.. (2004) Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.. Bioorg Med Chem Lett, 14 (13): (3581-4). [PMID:15177479] [10.1021/op500134e] |
| 2. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al.. (2007) Patterns of somatic mutation in human cancer genomes.. Nature, 446 (7132): (153-8). [PMID:17344846] [10.1021/op500134e] |
| 3. Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G et al.. (2009) p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.. J Med Chem, 52 (20): (6257-69). [PMID:19772287] [10.1021/op500134e] |
| 4. Medina JR, Becker CJ, Blackledge CW, Duquenne C, Feng Y, Grant SW, Heerding D, Li WH, Miller WH, Romeril SP et al.. (2011) Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.. J Med Chem, 54 (6): (1871-95). [PMID:21341675] [10.1021/op500134e] |
| 5. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al.. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).. Blood, 114 (14): (2984-92). [PMID:19654408] [10.1021/op500134e] |
| 6. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.. Mol Cancer Ther, 7 (4): (829-40). [PMID:18413796] [10.1021/op500134e] |
| 7. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. (2013) Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.. Bioorg Med Chem Lett, 23 (11): (3248-52). [PMID:23639540] [10.1021/op500134e] |
| 8. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238] [10.1021/op500134e] |
| 9. Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB. (2014) Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.. J Med Chem, 57 (19): (7900-15). [PMID:25101911] [10.1021/op500134e] |
| 10. Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, Gerstberger T, Hofmann MH, Hohmann AF, Kessler D et al.. (2016) Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.. J Med Chem, 59 (10): (4462-75). [PMID:26914985] [10.1021/op500134e] |
| 11. Johnston CJC, Smyth DJ, Kodali RB, White MPJ, Harcus Y, Filbey KJ, Hewitson JP, Hinck CS, Ivens A, Kemter AM et al.. (2017) A structurally distinct TGF-β mimic from an intestinal helminth parasite potently induces regulatory T cells.. Nat Commun, 8 (1): (1741). [PMID:29170498] [10.1021/op500134e] |
| 12. Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW et al.. (2018) Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.. Oncotarget, 9 (6): (6659-6677). [PMID:29467918] [10.1021/op500134e] |
| 13. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al.. (2020) Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.. J Med Chem, 71 (13): (1755-70). [PMID:32787110] [10.1021/acs.jmedchem.0c00936] |
| 14. Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S, Wang R, Janson C, Smith W, Krysa G, Boullay V, De Gouville AC, Huet S, Hartley D.. (2004) Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.. J Med Chem, 47 (18): (4494-4506). [PMID:15317461] [10.1021/jm0400247] |
| 15. Gellibert F, de Gouville AC, Woolven J, Mathews N, Nguyen VL, Bertho-Ruault C, Patikis A, Grygielko ET, Laping NJ, Huet S.. (2006) Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.. J Med Chem, 49 (7): (2210-2221). [PMID:16570917] [10.1021/jm0509905] |
| 16. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P.. (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.. J Med Chem, 51 (21): (6642-6645). [PMID:18834107] [10.1021/jm800986w] |
| 17. Shomin CD, Meyer SC, Ghosh I.. (2009) Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling.. Bioorg Med Chem, 17 (17): (6196-6202). [PMID:19674907] [10.1016/j.bmc.2009.07.056] |
| 18. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML.. (2009) Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.. Bioorg Med Chem, 17 (21): (7562-7571). [PMID:19783149] [10.1016/j.bmc.2009.09.008] |
| 19. Geldenhuys WJ, Nakamura H.. (2010) 3D-QSAR and docking studies on transforming growth factor (TGF)-beta receptor 1 antagonists.. Bioorg Med Chem Lett, 20 (6): (1918-1923). [PMID:20176484] [10.1016/j.bmcl.2010.01.140] |
| 20. Deng X, Lim SM, Zhang J, Gray NS.. (2010) Broad spectrum alkynyl inhibitors of T315I Bcr-Abl.. Bioorg Med Chem Lett, 20 (14): (4196-4200). [PMID:20541934] [10.1016/j.bmcl.2010.05.043] |
| 21. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N.. (2012) Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.. Bioorg Med Chem Lett, 22 (14): (4613-4618). [PMID:22726925] [10.1016/j.bmcl.2012.05.090] |
| 22. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS.. (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (17): (5625-5629). [PMID:22863203] [10.1016/j.bmcl.2012.06.104] |
| 23. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M.. (2013) Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.. Bioorg Med Chem Lett, 23 (9): (2743-2749). [PMID:23522834] [10.1016/j.bmcl.2013.02.065] |
| 24. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L.. (2015) Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.. Bioorg Med Chem, 23 (21): (7000-7006). [PMID:26455654] [10.1016/j.bmc.2015.09.038] |
| 25. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J.. (2016) Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.. Bioorg Med Chem Lett, 26 (5): (1443-1451). [PMID:26852363] [10.1016/j.bmcl.2016.01.062] |
| 26. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800] [10.1016/j.bmcl.2016.04.079] |
| 27. Klaeger S, Heinzlmeir S and Wilhelm M et al. (2017) The target landscape of clinical kinase drugs.. Science, 358 (6367): [PMID:29191878] [10.1126/science.aan4368] |
| 28. Chen Y, Zheng Y, Jiang Q, Qin F, Zhang Y, Fu L, He G.. (2017) Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells.. Eur J Med Chem, 127 (997-1011). [PMID:27839788] [10.1016/j.ejmech.2016.11.009] |
| 29. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448] [10.1016/j.bmc.2017.12.020] |
| 30. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J.. (2018) Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.. Eur J Med Chem, 150 (366-384). [PMID:29544149] [10.1016/j.ejmech.2018.03.003] |
| 31. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG.. (2018) Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells.. Bioorg Med Chem, 26 (14): (3899-3908). [PMID:29921474] [10.1016/j.bmc.2018.06.010] |
| 32. Hudson L, Mui J, Vázquez S, Carvalho DM, Williams E, Jones C, Bullock AN, Hoelder S.. (2018) Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept.. J Med Chem, 61 (16): (7261-7272). [PMID:30085668] [10.1021/acs.jmedchem.8b00782] |
| 33. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.. (2018) Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.. Bioorg Med Chem Lett, 28 (20): (3356-3362). [PMID:30227946] [10.1016/j.bmcl.2018.09.006] |
| 34. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q.. (2018) Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.. Eur J Med Chem, 158 (896-916). [PMID:30253346] [10.1016/j.ejmech.2018.09.025] |
| 35. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M.. (2019) Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis.. ACS Med Chem Lett, 10 (9): (1272-1278). [PMID:31531196] [10.1021/acsmedchemlett.9b00142] |
| 36. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L.. (2019) Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer.. Eur J Med Chem, 184 (111728-111728). [PMID:31610375] [10.1016/j.ejmech.2019.111728] |
| 37. Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK.. (2019) ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.. Eur J Med Chem, 161 (456-467). [PMID:30384048] [10.1016/j.ejmech.2018.10.052] |
| 38. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z.. (2019) Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.. Eur J Med Chem, 171 (221-234). [PMID:30925338] [10.1016/j.ejmech.2019.03.039] |
| 39. Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R.. (2019) Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.. Eur J Med Chem, 181 (111535-111535). [PMID:31376566] [10.1016/j.ejmech.2019.07.038] |
| 40. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S.. (2019) Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models.. J Med Chem, 62 (23): (10691-10710). [PMID:31693351] [10.1021/acs.jmedchem.9b01143] |
| 41. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS.. (2017) Discovery of a potent dual ALK and EGFR T790M inhibitor.. Eur J Med Chem, 136 (497-510). [PMID:28528303] [10.1016/j.ejmech.2017.04.079] |
| 42. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY.. (2019) Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3.. Eur J Med Chem, 168 (58-77). [PMID:30798053] [10.1016/j.ejmech.2018.12.063] |
| 43. Ensan D, Smil D, Zepeda-Velázquez CA, Panagopoulos D, Wong JF, Williams EP, Adamson R, Bullock AN, Kiyota T, Aman A, Roberts OG, Edwards AM, O'Meara JA, Isaac MB, Al-Awar R.. (2020) Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.. J Med Chem, 63 (9): (4978-4996). [PMID:32369358] [10.1021/acs.jmedchem.0c00395] |
| 44. Li YW, Li XY, Li S, Zhao LM, Ma J, Piao HR, Jiang Z, Jin CH, Jin X.. (2020) Synthesis and evaluation of the HIF-1α inhibitory activity of 3(5)-substituted-4-(quinolin-4-yl)- and 4-(2-phenylpyridin-4-yl)pyrazoles as inhibitors of ALK5.. Bioorg Med Chem Lett, 30 (2): (126822-126822). [PMID:31810777] [10.1016/j.bmcl.2019.126822] |
| 45. Smil D, Wong JF, Williams EP, Adamson RJ, Howarth A, McLeod DA, Mamai A, Kim S, Wilson BJ, Kiyota T, Aman A, Owen J, Poda G, Horiuchi KY, Kuznetsova E, Ma H, Hamblin JN, Cramp S, Roberts OG, Edwards AM, Uehling D, Al-Awar R, Bullock AN, O'Meara JA, Isaac MB.. (2020) Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.. J Med Chem, 63 (17): (10061-10085). [PMID:32787083] [10.1021/acs.jmedchem.0c01199] |
| 46. Hamilton GL,Chen H,Deshmukh G,Eigenbrot C,Fong R,Johnson A,Kohli PB,Lupardus PJ,Liederer BM,Ramaswamy S,Wang H,Wang J,Xu Z,Zhu Y,Vucic D,Patel S. (2019) Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group.. Bioorg Med Chem Lett, 29 (12.0): (1497-1501). [PMID:31000154] [10.1016/j.bmcl.2019.04.014] |
| 47. Engers DW,Bollinger SR,Felts AS,Vadukoot AK,Williams CH,Blobaum AL,Lindsley CW,Hong CC,Hopkins CR. (2020) Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.. Bioorg Med Chem Lett, 30 (18): (127418-127418). [PMID:32750526] [10.1016/j.bmcl.2020.127418] |
| 48. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY. (2018) Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.. Eur J Med Chem, 143 (1148-1164). [PMID:29133048] [10.1016/j.ejmech.2017.09.018] |
| 49. Xu G,Zhang Y,Wang H,Guo Z,Wang X,Li X,Chang S,Sun T,Yu Z,Xu T,Zhao L,Wang Y,Yu W. (2020) Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors.. Eur J Med Chem, 198 (112354-112354). [PMID:32387837] [10.1016/j.ejmech.2020.112354] |
| 50. Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, Zhang Y, Geng M, Huang M, Liu H.. (2022) Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors.. J Med Chem, 65 (2.0): (1243-1264). [PMID:33586434] [10.1021/acs.jmedchem.0c02111] |
| 51. Wieser, R R, Wrana, J L JL and Massagué, J J.. (1995) GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex.. The EMBO journal, (15): [PMID:7774578] |
| 52. Franzén, P P and 6 more authors.. (1993) Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor.. Cell, (19): [PMID:8242743] |
| 53. Jokiranta, T S TS, Tissari, J J, Teleman, O O and Meri, S S.. (1995) Extracellular domain of type I receptor for transforming growth factor-beta: molecular modelling using protectin (CD59) as a template.. FEBS letters, (27): [PMID:8521960] |
| 54. Eppert, K K and 12 more authors.. (1996) MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.. Cell, (23): [PMID:8752209] |
| 55. Macías-Silva, M M and 5 more authors.. (1996) MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling.. Cell, (27): [PMID:8980228] |
| 56. Nakao, A A and 10 more authors.. (1997) TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.. The EMBO journal, (1): [PMID:9311995] |
| 57. Abdollah, S S and 5 more authors.. (1997) TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling.. The Journal of biological chemistry, (31): [PMID:9346908] |
| 58. Vellucci, V F VF and Reiss, M M.. (1997) Cloning and genomic organization of the human transforming growth factor-beta type I receptor gene.. Genomics, (1): [PMID:9417915] |
| 59. Gilboa, L L, Wells, R G RG, Lodish, H F HF and Henis, Y I YI.. (1998) Oligomeric structure of type I and type II transforming growth factor beta receptors: homodimers form in the ER and persist at the plasma membrane.. The Journal of cell biology, (23): [PMID:9472030] |
| 60. Pasche, B B and 12 more authors.. (1998) Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract.. Cancer research, (1): [PMID:9661882] |
| 61. Massagué, J J.. (1998) TGF-beta signal transduction.. Annual review of biochemistry, [PMID:9759503] |
| 62. Tsukazaki, T T, Chiang, T A TA, Davison, A F AF, Attisano, L L and Wrana, J L JL.. (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor.. Cell, (11): [PMID:9865696] |
| 63. Huse, M M, Chen, Y G YG, Massagué, J J and Kuriyan, J J.. (1999) Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12.. Cell, (5): [PMID:10025408] |
| 64. Kavsak, P P and 6 more authors.. (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation.. Molecular cell, [PMID:11163210] |
| 65. Ebisawa, T T and 6 more authors.. (2001) Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation.. The Journal of biological chemistry, (20): [PMID:11278251] |
| 66. Huse, M M and 5 more authors.. (2001) The TGF beta receptor activation process: an inhibitor- to substrate-binding switch.. Molecular cell, [PMID:11583628] |
| 67. Felici, Angelina A and 7 more authors.. (2003) TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling.. The EMBO journal, (1): [PMID:12941698] |
| 68. Kaklamani, Virginia G VG and 8 more authors.. (2003) TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (1): [PMID:12947057] |
| 69. Humphray, S J SJ and 147 more authors.. (2004) DNA sequence and analysis of human chromosome 9.. Nature, (27): [PMID:15164053] |
| 70. Kaklamani, Virginia V and 10 more authors.. (2004) No major association between TGFBR1*6A and prostate cancer.. BMC genetics, (22): [PMID:15385056] |
| 71. Kuratomi, Go G and 6 more authors.. (2005) NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor.. The Biochemical journal, (15): [PMID:15496141] |
| 72. Suarez, B K BK and 8 more authors.. (2005) TGFBR1*6A is not associated with prostate cancer in men of European ancestry.. Prostate cancer and prostatic diseases, [PMID:15505640] |
| 73. Loeys, Bart L BL and 23 more authors.. (2005) A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2.. Nature genetics, [PMID:15731757] |
| 74. Ozdamar, Barish B and 5 more authors.. (2005) Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity.. Science (New York, N.Y.), (11): [PMID:15761148] |
| 75. Adès, L C LC and 10 more authors.. (2006) FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited.. American journal of medical genetics. Part A, (15): [PMID:16596670] |
| 76. Finnson, Kenneth W KW and 7 more authors.. (2006) Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, [PMID:16754747] |
| 77. Mátyás, Gábor G and 6 more authors.. (2006) Identification and in silico analyses of novel TGFBR1 and TGFBR2 mutations in Marfan syndrome-related disorders.. Human mutation, [PMID:16791849] |
| 78. Loeys, Bart L BL and 20 more authors.. (2006) Aneurysm syndromes caused by mutations in the TGF-beta receptor.. The New England journal of medicine, (24): [PMID:16928994] |
| 79. Sun, Yan Y and 9 more authors.. (2006) Potentiation of Smad-mediated transcriptional activation by the RNA-binding protein RBPMS.. Nucleic acids research, [PMID:17099224] |
| 80. Konrad, Lutz L and 8 more authors.. (2007) Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells.. BMC genomics, (11): [PMID:17845732] |
| 81. Groppe, Jay J and 8 more authors.. (2008) Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding.. Molecular cell, (1): [PMID:18243111] |
| 82. Sorrentino, Alessandro A and 8 more authors.. (2008) The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner.. Nature cell biology, [PMID:18758450] |
| 83. Ley, Timothy J TJ and 47 more authors.. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.. Nature, (6): [PMID:18987736] |
| 84. Drera, Bruno B and 8 more authors.. (2009) Loeys-Dietz syndrome type I and type II: clinical findings and novel mutations in two Italian patients.. Orphanet journal of rare diseases, (2): [PMID:19883511] |
| 85. Hao, Jijun and 8 more authors.. (2010) In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.. ACS chemical biology, (19): [PMID:20020776] |
| 86. Goudie, David R DR and 22 more authors.. (2011) Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1.. Nature genetics, (27): [PMID:21358634] |
| 87. Yang, Jeong Hoon JH and 8 more authors.. (2012) Clinical features and genetic analysis of Korean patients with Loeys-Dietz syndrome.. Journal of human genetics, [PMID:22113417] |
| 88. Eichhorn, Pieter J A PJ and 16 more authors.. (2012) USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma.. Nature medicine, (19): [PMID:22344298] |
| 89. Hwangbo, C C and 7 more authors.. (2016) Syntenin regulates TGF-β1-induced Smad activation and the epithelial-to-mesenchymal transition by inhibiting caveolin-mediated TGF-β type I receptor internalization.. Oncogene, (21): [PMID:25893292] |
| 90. Song, Jie J and 6 more authors.. (2016) APPL proteins promote TGFβ-induced nuclear transport of the TGFβ type I receptor intracellular domain.. Oncotarget, (5): [PMID:26583432] |
| 91. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC. (2018) Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.. Bioorg Med Chem Lett, 28 (10): (1964-1971). [PMID:29636220] [10.1016/j.bmcl.2018.03.032] |
